inammation at the time of inury). In addition, studies have shown it to reduce swelling of acute inammation and inhibit bone/cartilage degeneration with chronic in- ammation.19-


In a landmark study, the combination of C-II and ThiAA was shown to promote oint health, specically by positively inuencing knee extension (knee extension is necessary for daily function and sports activities). Additional ndings reveal the combination allowed individuals to exercise for longer periods of time before experiencing oint discomfort and to recover from oint inury faster.6-


Recent breakthrough research at Harvard, Stanford and niversity of ebraska conrms the supplemental value of the combination of C-II and ThiAA to maintain and revitalie oint function.8 profound impact on oint health.


These results can make a


ased on the numerous research studies conducted, there is a denitive need to augment soft tissue healing by adding proper supplementation because soft tissues do not heal properly by themselves. The three phases of care outlined in this article have been formulated for doctors of chiropractic to follow as a template for soft tissue inuries to ensure proper healing.


In my opinion, soft tissue and oint inury are not two separate units but are intricately related. Maintaining oint health is critical for adults through the lifespan to prevent soft tissue inury during ADL’s as well as exercise.


Proper diet, ergonomically sound body movement and nutritional supplements are keys for maintaining soft- tissue and oint health. Without nutritional supplements, the normal aging process of soft-tissue/oints will be exponentially increased.


About The Author Dr. Silverman graduated Magna cum Laude from the niversity of ridgeport College of Chiropractic and has a Masters of Science in Human utrition. His extensive list of educational accomplishments includes his designations as a certied nutrition specialist, certied clinical nutritionist, certied strength and conditioning specialist, certied Kinesio taping practitioner, ASM-certied corrective exercise specialist, and a certied sports nutritionist from The International Society of Sports utrition. Dr. Silverman is a diplomate with the American Clinical oard of utrition and diplomate with the Chiropractic oard of Clinical utrition. Dr. Silverman is also HardStyle Kettlebell Certied instructor, a certied RockTape  Fascial Movement Taping (levels 1  ) provider, and also a CrossFit Level 1 trainer. He has a full-time successful private practice in White Plains, Y, where he specialies in the treatment of oint pain with innovative, science-based, non- surgical approaches and functional medicine. He is a nationally and internationally known speaker and author, contributing to articles published in Dynamic Chiropractic, JACA, ACA ews, Chiropractic Economics, The Original Internist, Holistic Primary Care. Dr. Silverman is also on the advisory board for the Functional Medicine niversity, a health contributor to Fox ews Radio and has appeared on Fox  Friends and CS ews as a health expert. Dr. Silverman is awarded the “01 Sports Chiropractor of the Year” by the ACA Sports Council. Dr. Silverman can be reached at his ofce 91.8.66; email infoDrRobertSilverman.com www.DrRobertSilverman.com


12


2. Lugo JP, Saiyed M, Lau FC, et al. J Int Soc Sports utr. 2013;10(1)8


Reference 1. Crowley DC, Lau FC, Sharma P, et al. Int Med Sci. 009;631- 31


3. Marone PA, Lau FC, upta RC, et al. Toxicol Mech Methods. 2010;20()1-189


4. arnett ML, Kremer JM, et al. Arthritis Rheum. 1998;41(2)290- 29


. Ostrowski K, Rohde T, et al. Pro- and anti-inammatory cytokine balance in strenuous in humans. J Physiol. 1999 Feb 1;1 (Pt 1)28-91


6. Kiviranta I, Tammi M, Jurvelin J, et al. Articular cartilage thickness and glycosaminoglycan distribution in the canine knee oint after strenuous running exercise. Clin Orthop Relat Res. 1992 Oct;(283)302-8


8. Wang Q, Roelle AL, Lepus CM, et al. Identication of a central role for complement in osteoarthritis. at Med. 2011 ov 6


9. http//med.stanford.edu/ism/2011/november/osteoarthritis.html. Accessed ovember 1, 2011


. Hoff P, uttgereit F, urmester R, et al. Osteoarthritis synovial uid activates pro-inammatory cytokines in primary human chondrocytes. Int Orthop. 2013 Jan;3(1)14-1


11. Min SY, Park KS, Cho ML, et al. Antigen-induced, tolerogenic CD11c,CD11b dendritic cells are abundant in Peyer’s patches during the induction of oral tolerance to type II collagen and suppress experimental collagen-induced arthritis. Rheum. 2006 Mar;4(3)88-98.


12. Weiner HL. Oral tolerance immune mechanisms and treatment of autoimmune diseases. Immunol Today. 199 Jul;18()33-43.


13. agchi D, Misner , agchi M, et al. Effects of orally administered undenatured type II collagen against arthritic inammatory diseases a mechanistic exploration. Int J Clin Pharmacol Res. 2002;22(3-4)101-10


10. Rennard O, Ertl RF, ossman L, Robbins RA, Rennard SI. Chicken soup inhibits neutrophil chemotaxis in vitro. Chest. 2000 Oct;118(4)110-


Arthritis


14. Cremer MA, Rosloniec EF, Kang AH. The cartilage collagens a review of their structure, organiation, and role in the pathogenesis of experimental arthritis in animals and in human rheumatic disease. J Mol Med (erl). 1998 Mar;6(3-4)2-88


16. Recommendations for the medical management of osteoarthritis of the hip and knee 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis uidelines. Arthritis Rheum. 2000 Sep;43(9)190-1


18. Desaia A, Konda R, et al. Inamm Res. 2009;8()229-234 19. Desai A, Darland , land JS, et al. Atherosclerosis. 2012;223(1)130-136


21. Tripp M, Darland , Lerman RH et al. Presented at Fed Am Soc Experimental iol. 2003 April


22. Lerman RH, Liska D, et al. Proprietary Clinical Research Report. ig Harbor, WA Functional Medicine Research Center; 2004


1. Corthay A, acklund J, roddefalk J, et al. Epitope glycosylation plays a critical role for T cell recognition of type II collagen in collagen-induced arthritis. Eur J Immunol. 1998 Aug;28(8)280- 90


1. Park KS, Park MJ, Cho ML, et al. Type II collagen oral tolerance; mechanism and role in collagen-induced arthritis and rheumatoid arthritis. Mod Rheumatol. 2009;19(6)81-9


20. 20) Konda R, Desai A, Darland , et al. Arthritis Rheum. 2010;62(6)1683-1692


23. Lerman RH, Liska D, Tripp M, et al. Proprietary Clinical Research Report. ig Harbor, WA Functional Medicine Research Center; 2004


2. Minich DM, land JS, Katke J, et al. J Physiol Pharmacol. 200;882-883


26. Lerman RH. Proprietary Clinical Research Report. ig Harbor, WA Functional Medicine Research Center; 2013


24. Lukacer D, Lerman RH, Tripp M, et al. Proprietary Clinical Research Report. ig Harbor, WA Functional Medicine Research Center; 2004


2. JP Lugo, M Saiyed, FC Lau, et al. ndenatured type II collagen (C-II) for oint support a randomied, double-blind, placebo- controlled study in healthy volunteers. Journal of the International Society of Sports utrition 2013, 1048


28. Trentham DE, Dynesius-Trentham RA, Orav EJ, et al. Effects of oral administration of type II collagen on rheumatoid arthritis.


Science. 1993 Sep 24;261(129)12-30 THE ORIGINAL INTERNIST MARCH 01


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52